Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00235274|
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : March 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Subcutaneous Secretin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effects of RG1068 (Secretin) on Information Processing in Schizophrenia|
|Study Start Date :||November 2005|
|Estimated Study Completion Date :||August 2006|
- Motor learning will be assessed with a classical eye-blink conditioning procedure, requiring the learning of a reflexive eye-blink response to a weak puff of air to the eye.
- Effects of Secretin will be tested on affect modulation, pre-pulse inhibition, and pre-pulse facilitation of the acoustic startle response using common psychophysiological research procedures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235274
|United States, Indiana|
|LaRue Carter Hospital|
|Indianapolis, Indiana, United States, 46202|
|Principal Investigator:||Anantha Shekhar, MD, PhD||Indiana University School of Medicine|